Opportunities | Danae UroGenomics

The new generation of molecular urological diagnostics

The oncology diagnostics market is evolving towards non-invasive, more precise and scalable molecular solutions adapted to personalized medicine.

Molecular diagnostics

Personalized medicine

Scalable platform

Urine miRNA biomarkers analyzed through high-sensitivity RT-qPCR technology.

Tools designed to support clinical and therapeutic decision-making.

Technology adaptable to hospitals, laboratories and international diagnostic networks.

>90%

33%

Non-invasive

$9.2B

Clinical precision

Lower cost

Urine sample

Market opportunity

An unmet medical and economic need

Bladder cancer has a high recurrence rate and requires long-term monitoring, creating a significant burden for patients, hospitals and healthcare systems.

+550,000

+70%

€150,000

annual global cases

recurrence rate

cost per patient

A significant global market with recurring needs for diagnosis and monitoring.

High recurrence multiplies the volume of follow-up procedures and accumulated costs.

One of the oncology indications with the highest accumulated economic burden.

The result: healthcare systems under pressure, saturated hospitals and a clear opportunity for non-invasive, precise and cost-effective molecular alternatives.

PROPRIETARY TECHNOLOGY

BlaDimiR Platform

Danae Urogenomics is developing a family of urine-based miRNA biomarker solutions with applications in diagnosis, monitoring and therapy response prediction.

Non-invasive diagnosis and monitoring of bladder cancer

Urine-based miRNA biomarkers
High sensitivity and specificity
Designed for clinical practice

Therapy response prediction

Advanced assessment of combination therapies

Supports clinical decision-making
Personalized medicine approach
Value for hospitals and networks

miRNAs + cytokines
Complex clinical contexts
Pipeline scalability

Explore the BlaDimiR platform

COMPETITIVE ADVANTAGE

Strategic differentiators

BlaDimiR combines molecular precision, lower cost, operational scalability and intellectual property protection in a platform with international expansion potential.

Superior precision

A simple molecular alternative designed to reduce reliance on invasive procedures.

Strong patents

Lower cost

BlaDimiRPLUS + BlaDimiRIO

Clinical precision based on urine miRNA biomarkers.

Non-invasive test

33%

Lower cost than competing solutions, improving adoption potential.

Proprietary pipeline

>90%

Expansion toward therapy response prediction and personalized medicine.

Intellectual property

Urine sample

Technology protected in key markets, supported by scientific evidence and international publications.

A differentiated platform designed to transform bladder cancer diagnosis, monitoring and therapeutic stratification.

SCALABLE MODEL

A recurring, high-margin business model

Danae Urogenomics combines test sales, consumables, platform deployment and licensing agreements to scale across hospitals, laboratories and international markets.

Tests + consumables

BlaDiCheck

Licensing & SaaS

Razor & blades model with hardware deployed in laboratories and recurring revenue generated through consumables

Revenue linked to test volume
Recurring use in diagnosis and monitoring
Application in hospitals and laboratories

Recurring sales of diagnostic kits and consumables associated with the clinical use of BlaDimiR.

International licensing
Recurring digital services
Expansion potential with global partners

Strategic agreements with diagnostics companies, royalties and digital services for maintenance, quality control and updates.

Operational platform for diagnostic centers
Lower adoption barriers
Scalability through installation and use

75%

Current gross margin

8–12%

Licensing royalties

80–85%

Projected gross margin

Explore partnership opportunities

ROADMAP

From clinical validation to international scale-up

Danae Urogenomics is advancing through a progressive strategy to clinically validate BlaDimiR, obtain regulatory certification and scale adoption across hospitals, laboratories, insurers and international partners.

2025 - 2026

2026 - 2027

2027 - 2028

2029 - 2030

Clinical validation

Certification and initial adoption

European expansion

Global licensing

Multicenter clinical studies and first pilot hospitals in Spain.

CE-IVD process launch, clinical evidence generation and first commercial sales.

Entry into key European markets and agreements with distributors and laboratories.

Strategic agreements with diagnostics companies and expansion towards the U.S. market.

Local validation → European expansion → Global licensing

TRACTION AND VALIDATION

Validated, protected and scientifically backed technology

Danae Urogenomics combines intellectual property, scientific publications, ongoing clinical validation and institutional support to advance BlaDimiR toward clinical and commercial adoption.

Intellectual property

Granted patent and international protection

Spanish patent granted, PCT application advanced in Europe and the U.S., and protection strategy focused on key markets.

Scientific evidence

Publications in specialized journals

Published results in peer-reviewed scientific journals support the robustness of urine-based miRNA biomarkers.

Clinical validation

Multicenter study underway

Clinical validation designed to support BlaDimiR integration into hospital and laboratory environments.

Support and adoption

Grants, hospitals and early contacts

Competitive institutional support, collaboration with reference hospitals and first steps toward commercial agreements.

A strong scientific, clinical and regulatory foundation to accelerate the commercial and international adoption of BlaDimiR.

Review scientific evidence

Let’s build the next generation of urological diagnostics together

STRATEGIC PARTNERSHIPS

Danae Urogenomics offers a science-backed molecular platform with international scale-up potential and applications in diagnosis, monitoring and personalized medicine. We are seeking strategic partners to accelerate clinical and commercial adoption.